Friday, March 11, 2022 8:40:51 AM
Session 405 - Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials
405-08 - A Pragmatic Randomized Trial Of Icosapent Ethyl For High Cardiovascular Risk Adults (mitigate) In An Era Of Coronavirus Disease 2019
Add to My Itinerary
April 3, 2022, 8:00 AM - 8:10 AM Main Tent, Hall D
Authors
Andrew P. Ambrosy, Thida Tan, Rachel Thomas, Rishi Parikh, Daniel Stevens, Ryan Wi, Harshith Avula, Matthew Solomon, Van Selby, Jesse Fitzpatrick, Choon Goh, Jacek Skarbinski, Sephy Philip, Deepak Bhatt, Alan Go, Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA, Kaiser Permanente Northern California - Division of Research, Oakland, CA, USA
Abstract
Abstract is embargoed at this time.
Session 1188 - Prevention and Health Promotion: Lipids Digital Presentations
1188-004 / 4 - ICOSAPENT ETHYL REDUCES CARDIOVASCULAR RISK SUBSTANTIALLY AND CONSISTENTLY REGARDLESS OF WAIST CIRCUMFERENCE
Add to My Itinerary
April 2, 2022, 8:30 AM - 8:30 AM eAbstract site
Authors
Deepak L. Bhatt, Eliot A. Brinton, Michael Miller, Philippe Gabriel Steg, Terry A. Jacobson, Steven Ketchum, Lixia Jiao, Ralph T. Doyle, Jr, Jean Claude Tardif, Christie M. Ballantyne, on behalf of the REDUCE-IT Investigators, Brigham and Women’s Hospital, Boston, MA, USA
Abstract
Abstract is embargoed at this time.
Session 1276 - Vascular Medicine: Pharmacology 2
1276-082 / 82 - EICOSAPENTAENOIC ACID (EPA) COMBINED WITH HIGH INTENSITY STATINS REDUCE LIPID OXIDATION IN MODEL MEMBRANES
Add to My Itinerary
April 2, 2022, 10:45 AM - 11:30 AM Poster Hall, Hall C
Authors
Samuel R. Sherratt, Peter Libby, Deepak L. Bhatt, R. Preston Mason, University of New Hampshire, Durham, NH, USA, Elucida Research LLC, Beverly, MA, USA
Abstract
Abstract is embargoed at this time.
Session 1453 - Vascular Medicine: Basic and Translational Science 11
1453-077 / 77 - EICOSAPENTAENOIC ACID (EPA) INCREASES HEME OXYGENASE-1 EXPRESSION IN MACROPHAGES AND ENDOTHELIAL CELLS DURING INFLAMMATION
Add to My Itinerary
April 3, 2022, 2:45 PM - 3:30 PM Poster Hall, Hall C
Authors
Samuel CR R. Sherratt, Peter Libby, Deepak L. Bhatt, Hazem Dawoud, Tadeusz Malinski, R. Preston Mason, University of New Hampshire, Durham, NH, USA, Elucida Research LLC, Beverly, MA, USA
Abstract
Abstract is embargoed at this time.
Session 1453 - Vascular Medicine: Basic and Translational Science 11
1453-078 / 78 - EICOSAPENTAENOIC ACID (EPA) DECREASES ANGIOTENSIN CONVERTING ENZYME (ACE) EXPRESSION IN VASCULAR AND PULMONARY ENDOTHELIUM FOLLOWING CYTOKINE CHALLENGE
Add to My Itinerary
April 3, 2022, 2:45 PM - 3:30 PM Poster Hall, Hall C
Authors
Samuel CR R. Sherratt, Peter Libby, Deepak L. Bhatt, Hazem Dawoud, Tadeusz Malinski, R. Preston Mason, University of New Hampshire, Durham, MA, USA, Elucida Research LLC, Beverly, MA, USA
Abstract
Abstract is embargoed at this time.
Session 1453 - Vascular Medicine: Basic and Translational Science 11
1453-079 / 79 - EICOSAPENTAENOIC ACID (EPA) REDUCES INFLAMMATION AND IMPROVES NITRIC OXIDE BIOAVAILABILITY IN PULMONARY ENDOTHELIAL CELLS FOLLOWING EXPOSURE TO AIR POLLUTION PARTICLES
Add to My Itinerary
April 3, 2022, 2:45 PM - 3:30 PM Poster Hall, Hall C
Authors
Samuel CR R. Sherratt, Hazem Dawoud, Peter Libby, Deepak L. Bhatt, Tadeusz Malinski, R. Preston Mason, University of New Hampshire, Durham, NH, USA, Elucida Research LLC, Beverly, MA, USA
Abstract
Abstract is embargoed at this time.
Session 1108 - Vascular Medicine Basic/Translational Science: Moderated Poster Contributions
1108-03 - EICOSAPENTAENOIC ACID (EPA) REDUCES J774 MACROPHAGE ACTIVATION AND CYCLOOXYGENASE (COX-1) EXPRESSION
Add to My Itinerary
April 4, 2022, 10:00 AM - 10:10 AM Special Topics Moderated Poster Theater 5_Hall C
Authors
Samuel CR R. Sherratt, Peter Libby, Deepak L. Bhatt, Hazem Dawoud, Tadeusz Malinski, R. Preston Mason, University of New Hampshire, Durham, NH, USA, Elucida Research LLC, Beverly, MA, USA
Abstract
Abstract is embargoed at this time.
Recent AMRN News
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:31:21 PM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONG • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM